Today before the opening bell, Galena announced that Executive Vice President and Chief Operating Officer Mark W. Schwartz, Ph.D., will provide a corporate update at the 12th Annual BIO Investor Forum. The presentation is scheduled for Wednesday, October 9, 2013 at 9:00 a.m. PT at The Palace Hotel in San Francisco, CA.
Galena Biopharma is focused on developing and commercializing targeted oncology treatments to address major unmet medical needs and advance cancer care. The company’s peptide vaccine immunotherapies harness the patient’s own immune system to identify and destroy cancer cells. Utilizing peptide immunogens has many clinical advantages, including an excellent safety profile and long-lasting protection through immune system activation and convenient delivery.
For more information please visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
